인간 생식 기술 시장 : 기술별, 지역별

Human Reproductive Technologies Market is estimated to be valued at USD 33.55 Bn in 2026 and is expected to reach USD 40.71 Bn by 2033, growing at a compound annual growth rate (CAGR) of 2.8% from 2026 to 2033.

Human reproductive technologies assist parents who are having troubles in pregnancies, and infertility issues. These technologies include Assisted Reproductive Technology (ART), prognostics, contraception, and same-sex procreation. ART aids in the treatment of low fertility or infertility using artificial insemination, artificial reproduction, cloning, cytoplasmic transfer, fertility medication, hormone treatment, and others. The second most common reason for using assisted reproductive technology is infertility. IVF completely omits the fallopian tubes for treating patients with tubal factor infertility. Male factor infertility, decreased ovarian reserve, ovarian failure (with donor eggs), ovulatory dysfunction, and unexplained infertility are among other infertility etiologies that can be treated with IVF. IVF can be utilized with a gestational carrier in patients for whom pregnancy is generally contraindicated (described below) or with uterine factor infertility. IVF is also used outside of infertility settings. It can be used in patients desiring preimplantation genetic testing before conception (such as those known to be carriers of certain genetic disorders), fertility preservation, such as prior to gonadotoxic therapy, or in patients desiring to delay childbearing. These women can opt to freeze their eggs or embryos if they are in a stable relationship. The high prevalence of maternal mortality, increasing population and increasing focus on family planning is expected to boost the global human reproductive technologies market over the forecast period.

Market Dynamics

The high prevalence of maternal mortality and increasing population had assisted the key players to focus on various growth strategies for the product launch as well as acquisitions, which will lead to the growth of global human reproductive technologies market over the forecast period. For instance, in May 2022, Perrigo Company plc., a provider of Consumer Self-Care Products, announced that it completed the acquisition of HRA Pharma, a global independent pharmaceutical company that engineers and commercializes drugs in the women's health and endocrinology segments. for US$ 1.9 billion based on current exchange rates, in cash, accelerating its position as a global consumer self-care company.

Key features of the study:

• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global human reproductive technologies market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study are Abbott, Evofem Biosciences, Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Perrigo Company plc., Uniprix, Lupin, Sandoz International GmbH, Aurobindo Pharma, Bayer AG, Lilly, GSK plc., Mankind Pharma, Church & Dwight Co., Inc., and Pfizer, Inc.
• Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global human reproductive technologies market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global human reproductive technologies market

Detailed Segmentation:

• Global Human Reproductive Technologies Market, By Technology (Revenue, USD Bn, 2021 - 2033)
• Infertility Drugs
• Contraceptive Drugs and Devices
• Global Human Reproductive Technologies Market, By Region (Revenue, USD Bn, 2021 - 2033)
• North America
  • U.S.
  • Canada
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • GCC
  • Israel
  • Rest of Middle East
• Africa
  • South Africa
  • Central Africa
  • North Africa
• Company Profiles
• Abbott
• Evofem Biosciences, Inc.
• Teva Pharmaceutical Industries Ltd.
• Sun Pharmaceutical Industries Ltd.
• Perrigo Company plc.
• Uniprix
• Lupin
• Sandoz International GmbH
• Aurobindo Pharma
• Bayer AG
• Lilly
• GSK plc.
• Mankind Pharma
• Church & Dwight Co., Inc.
• Pfizer, Inc.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Technology
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Attractiveness Analysis
  • Market Opportunities
  • Merger, Acquisition, Collaborations
  • Funding and Investment
  • Future Prospective of Viral Vector and Plasma DNA Testing
  • Regulatory Guideline and Compliances
  • Key Developments
  • PEST Analysis
  • PORTER's Analysis

4. Global Human Reproductive Technologies Market, By Technology, 2021 - 2033, (US$ Billion)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022-2033
  • Segment Trends
• Infertility Drugs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Billion)
• Contraceptive Drugs and Devices
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Billion)

5. Global Human Reproductive Technologies Market, By Region, 2021 - 2033, (US$ Billion)

• Introduction
  • Market Share Analysis, By Region, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, For Region, 2022-2033
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2021 - 2033, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Billion)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2021 - 2033, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Billion)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2021 - 2033, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Billion)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2021 - 2033, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Billion)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2021 - 2033, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Billion)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2021 - 2033, (US$ Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (US$ Billion)
    • North Africa
    • Central Africa
    • South Africa

6. Competitive Landscape

• Abbott
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Evofem Biosciences, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Teva Pharmaceutical Industries Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Sun Pharmaceutical Industries Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Perrigo Company plc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Uniprix
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Lupin
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Sandoz International GmbH
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Aurobindo Pharma
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance.
  • Market Strategies
• Bayer AG
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Lilly
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• GSK plc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Mankind Pharma
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Church & Dwight Co., Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies

7. Section

• Research Methodology
• About Us